《Annals Of Pharmacotherapy》雜志影響因子：2.3。
期刊Annals Of Pharmacotherapy近年評(píng)價(jià)數(shù)據(jù)趨勢(shì)圖
期刊影響因子趨勢(shì)圖
以下是一些常見(jiàn)的影響因子查詢?nèi)肟冢?
（1）Web of Science：是查詢SCI期刊影響因子的權(quán)威平臺(tái)，收錄全球高質(zhì)量學(xué)術(shù)期刊，提供詳細(xì)的期刊引證報(bào)告，包括影響因子、分區(qū)、被引頻次等關(guān)鍵指標(biāo)。
（2）?Journal Citation Reports (JCR)：JCR是科睿唯安旗下的一個(gè)網(wǎng)站，提供了期刊影響因子、引用數(shù)據(jù)和相關(guān)指標(biāo)。用戶可以在該網(wǎng)站上查找特定期刊的影響因子信息。
（3）中科院SCI期刊分區(qū)表：提供中科院分區(qū)的期刊數(shù)據(jù)查詢，包括影響因子和分區(qū)信息。
《Annals Of Pharmacotherapy》雜志是由SAGE Publications Inc.出版社主辦的一本以醫(yī)學(xué)-藥學(xué)為研究方向，OA非開(kāi)放（Not Open Access）的國(guó)際優(yōu)秀期刊。
該雜志出版語(yǔ)言為Multi-Language，創(chuàng)刊于1992年。自創(chuàng)刊以來(lái)，已被SCIE（科學(xué)引文索引擴(kuò)展板）等國(guó)內(nèi)外知名檢索系統(tǒng)收錄。該雜志發(fā)表了高質(zhì)量的論文，重點(diǎn)介紹了PHARMACOLOGY & PHARMACY在分析和實(shí)踐中的理論、研究和應(yīng)用。
?學(xué)術(shù)地位：在JCR分區(qū)中位列Q3區(qū)，中科院分區(qū)為醫(yī)學(xué)大類4區(qū)，PHARMACOLOGY & PHARMACY藥學(xué)小類4區(qū)。
期刊發(fā)文分析
機(jī)構(gòu)發(fā)文量統(tǒng)計(jì)
| 機(jī)構(gòu) | 發(fā)文量 |
| STATE UNIVERSITY SYSTEM OF FLORIDA | 27 |
| US DEPARTMENT OF VETERANS AFFAIRS | 25 |
| CLEVELAND CLINIC FOUNDATION | 14 |
| OHIO STATE UNIVERSITY | 14 |
| STATE UNIVERSITY OF NEW YORK (SUNY) SYSTEM | 14 |
| UNIVERSITY OF MICHIGAN SYSTEM | 14 |
| MEDICAL UNIVERSITY OF SOUTH CAROLINA | 13 |
| UNIVERSITY OF COLORADO SYSTEM | 13 |
| UNIVERSITY OF CONNECTICUT | 13 |
| UNIVERSITY OF NORTH CAROLINA | 13 |
國(guó)家 / 地區(qū)發(fā)文量統(tǒng)計(jì)
| 國(guó)家 / 地區(qū) | 發(fā)文量 |
| USA | 475 |
| Canada | 25 |
| Australia | 14 |
| CHINA MAINLAND | 14 |
| Japan | 9 |
| France | 7 |
| Italy | 6 |
| Spain | 6 |
| England | 4 |
| Israel | 4 |
期刊引用數(shù)據(jù)次數(shù)統(tǒng)計(jì)
| 期刊引用數(shù)據(jù) | 引用次數(shù) |
| NEW ENGL J MED | 151 |
| ANN PHARMACOTHER | 90 |
| CLIN INFECT DIS | 90 |
| JAMA-J AM MED ASSOC | 74 |
| LANCET | 63 |
| DIABETES CARE | 62 |
| ANTIMICROB AGENTS CH | 60 |
| CIRCULATION | 53 |
| J AM COLL CARDIOL | 50 |
| BLOOD | 47 |
期刊被引用數(shù)據(jù)次數(shù)統(tǒng)計(jì)
| 期刊被引用數(shù)據(jù) | 引用次數(shù) |
| ANN PHARMACOTHER | 90 |
| BMJ OPEN | 76 |
| INT J CLIN PHARM-NET | 75 |
| J AM PHARM ASSOC | 73 |
| PLOS ONE | 72 |
| AM J HEALTH-SYST PH | 53 |
| J ONCOL PHARM PRACT | 49 |
| PHARMACOTHERAPY | 49 |
| FRONT PHARMACOL | 48 |
| EUR J CLIN PHARMACOL | 40 |
文章引用數(shù)據(jù)次數(shù)統(tǒng)計(jì)
| 文章引用數(shù)據(jù) | 引用次數(shù) |
| Cost of Prescription Drug-Related Morbidit... | 28 |
| Cannabidiol: A New Hope for Patients With ... | 22 |
| Baricitinib: The Second FDA-Approved JAK I... | 20 |
| Comparing the Efficacy and Safety of Direc... | 19 |
| Safety and Efficacy of Apixaban Versus War... | 14 |
| Associations Between Potentially Inappropr... | 13 |
| Impact of Deuterium Substitution on the Ph... | 12 |
| Comparison of the Nephrotoxicity of Vancom... | 12 |
| Optimizing the Treatment of Steroid-Induce... | 12 |
| Medication Regimen Complexity Measured by ... | 11 |
